Costunolide ameliorates angiotensin II-induced atrial inflammation and fibrosis by regulating mitochondrial function and oxidative stress in mice: A possible therapeutic approach for atrial fibrillation
Microvascular Research · 2024
DOI: 10.1016/j.mvr.2023.104600 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microvascular Research, 2024. Verfasst von Yushu Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang, PR China. Hauptthemen laut MEDLINE: Atrial Fibrillation, Sesquiterpenes, Mitochondrial Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 62 Literaturangaben.
Abstract (Originalsprache)
Atrial fibrillation (AF) is a cardiac disease characterized by disordered atrial electrical activity. Atrial inflammation and fibrosis are involved in AF progression. Costunolide (COS) is a sesquiterpene lactone containing anti-inflammatory and anti-fibrotic activities. This study aims to explore the underlying mechanisms by which COS protects against AF. Male C57BL/6 mice (8- to 10-week-old) were infused with angiotensin (Ang) II for 3 weeks. Meanwhile, different doses of COS (COS-L: 10 mg/kg, COS-H: 20 mg/kg) were administered to mice by intragastric treatment. The results showed irregular and rapid heart rates in Ang II-treated mice. Moreover, the levels of inflammatory cytokines and fibrotic factors were elevated in mice. COS triggered a reduction of Ang II-induced inflammation and fibrosis, which conferred a protective effect. Mechanistically, mitochondrial dysfunction with mitochondrial respiration inhibition and aberrant ATP levels were observed after Ang II treatment. Moreover, Ang-II-induced excessive reactive oxygen species caused oxidative stress, which was further aggravated by inhibiting Nrf2 nuclear translocation. Importantly, COS diminished these Ang-II-mediated effects in mice. In conclusion, COS attenuated inflammation and fibrosis in Ang-II-treated mice by alleviating mitochondrial dysfunction and oxidative stress. Our findings represent a potential therapeutic option for AF treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang, PR China.
- Department of Nutrition and Food Hygiene, School of Public Health, Mudanjiang Medical University, Mudanjiang 157011, Heilongjiang, PR China.
- Department of General Practice, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang, PR China.
- Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang, PR China.
- Graduate Student, Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang, PR China.
- Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang, PR China. Electronic address: Liweimin_2009@163.com.
Zitieren
APA
Liu, Y., Wang, D., Jin, Y., Sun, G., Lou, Q., Wang, H., & Li, W. (2024). Costunolide ameliorates angiotensin II-induced atrial inflammation and fibrosis by regulating mitochondrial function and oxidative stress in mice: A possible therapeutic approach for atrial fibrillation. Microvascular Research. https://doi.org/10.1016/j.mvr.2023.104600
Vancouver
Liu Y, Wang D, Jin Y, Sun G, Lou Q, Wang H, et al. Costunolide ameliorates angiotensin II-induced atrial inflammation and fibrosis by regulating mitochondrial function and oxidative stress in mice: A possible therapeutic approach for atrial fibrillation. Microvascular Research. 2024. doi:10.1016/j.mvr.2023.104600
BibTeX
@article{Liu2024,
author = {Liu, Yushu and Wang, Dong and Jin, Yimin and Sun, Guifang and Lou, Qi and Wang, Hong and Li, Weimin},
title = {Costunolide ameliorates angiotensin II-induced atrial inflammation and fibrosis by regulating mitochondrial function and oxidative stress in mice: A possible therapeutic approach for atrial fibrillation},
journal = {Microvascular Research},
year = {2024},
doi = {10.1016/j.mvr.2023.104600}
}
EUVIMED